Evidence map›Paper›PMID 31123647›Full record

ArticleCureus2019

Sjogren's Syndrome: Clinical Benefits of Low-dose Naltrexone Therapy.

Scott Zashin

2 registry-linked trialsOpen access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Cureus, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04250792 phase1completednot on this map

Efficacy of Low Dose Naltrexone in Psoriasis; Clinical Trial in a Tertiary Care Hospital of Karachi.

TypeinterventionalSponsorJinnah Postgraduate Medical CentreRan2019 to 2019Enrolled42ConditionsPsoriasisArmsNaltrexone Pill
NCT04313972 phase4terminatednot on this mapstarted 2021, after this paper: background citation

IC PaIN Trial: Interstitial Cystitis Pain Improvement With Naltrexone, the Effect of Low Dose Naltrexone on Symptoms and Pain of Patients With Interstitial Cystitis/Painful Bladder Syndrome a Randomized Placebo-controlled Prospective Trial

TypeinterventionalSponsorEndeavor HealthRan2021 to 2023Enrolled3ConditionsInterstitial Cystitis, Painful Bladder Syndrome, Bladder Pain Syndrome, Low Dose NaltrexoneArmslow-dose naltrexone, Placebo oral tablet
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Low-Dose Naltrexone in Rheumatological Diseases.Mediterranean journal of rheumatology · 2023
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Scott ZashinRheumatology, University of Texas Southwest Medical Center, Dallas, USA.
The University of Texas Southwestern Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sjogren's Syndrome is a chronic autoimmune disorder that causes the inflammation of the lacrimal and salivary glands, resulting in dryness of the eyes and mouth. In addition, fatigue and musculoskeletal pain, often described as aching, is very common. Treatment directed toward alleviating the fatigue and pain associated with Sjogren's is currently very limited. This report describes a case of a 47-year-old female with suspected Sjogren's based on long-standing dry eyes, dry mouth, joint pain, fatigue, elevated measures of inflammation, and a positive rheumatoid factor. She failed standard therapy but improved clinically with low-dose naltrexone therapy.

Indexed as

autoimmune diseasesfatiguejoint painlow dose naltrexonesjogren syndrome

Identifiers

PMID31123647
PMCPMC6510571
OpenAlexW2922213961

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.